Elixxer Ltd.

As of December 31, 2025, Elixxer Ltd. carries a market capitalization of 126,765.98, placing it among publicly traded companies globally. Its enterprise value stands at 7.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Elixxer Ltd. has 11.34M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Elixxer Ltd. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -98.25, indicating conservative leverage, while an interest coverage ratio of -0.30 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -242.31, reflecting losses generated across the asset base.

As of the close on October 6, 2026, Elixxer Ltd.'s stock has declined approximately 100.00% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 1.02.

Over the twelve months ended December 31, 2025, Elixxer Ltd. generated - - in revenue and converted that into -2.82M in net income, yielding earnings per share of -0.25. EBITDA reached -486,123.91, while operating income came in at -486,123.91.

As of December 31, 2025, Elixxer Ltd. holds 25,599.13 in cash and equivalents against 7.20M in total debt, resulting in a net debt position of 7.17M. Total book value stands at -7.33M, with working capital of -8.07M providing operational flexibility.

Elixxer Ltd. produced -513,978.86 in operating cash flow over the twelve months ended December 31, 2025.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -405.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -413.98, meaning Elixxer Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Elixxer Ltd.'s most recent stock split took place on February 10, 2022 with a 100:1 split ratio.

As of December 31, 2025, Elixxer Ltd. has an Altman Z-Score of -135.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.